The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results.
 
Howard Safran
No Relationships to Disclose
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
 
Cecile Vicier
Honoraria - seagen
Consulting or Advisory Role - Novartis (Inst); Owkin; Pfizer
Research Funding - BMS Norway (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Novartis; Pfizer
 
Frederic Forget
Travel, Accommodations, Expenses - ipsen; Teva
 
Carlos A. Gomez-Roca
Honoraria - Bristol-Myers Squibb; Eisai; Foundation Medicine; Genentech/Roche; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Ellipses Pharma; Macomics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech
Travel, Accommodations, Expenses - MSD Oncology; Pierre Fabre; Roche/Genentech
 
Nicolas Penel
Research Funding - Bayer (Inst); Bayer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Astellas Pharma; Janssen-Cilag
Other Relationship - PharmaMar
 
Mario Campone
Honoraria - Lilly; Novartis
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Daiichi Sankyo Europe GmbH; Diaccurate (Inst); Lilly (Inst); Menarini; Novartis (Inst); PET-THERAPY (Inst); Pfizer; Pierre Fabre (Inst); Sandoz-Novartis (Inst); Sanofi (Inst); Seagen (Inst)
Speakers' Bureau - Amgen; Lilly (Inst); Novartis
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer
Other Relationship - Roche
 
Emanuela Romano
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
Research Funding - Amgen; Bristol-Myers Squibb; Replimune (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Roche
 
Jennifer Brooke Valerin
Speakers' Bureau - AstraZeneca
 
Guy Heinrich Maria Jerusalem
Honoraria - AstraZeneca; Bristol-Myers Squibb; Daiichy Sankyo; Lilly; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS; Lilly; Medimmune; Merck; Novartis; Pfizer; Roche
 
Anthony B. El-Khoueiry
Honoraria - ABL bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EISAI; EMD Serono; Exelixis; Gilead Sciences; Merck; QED Therapeutics; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; Tallac Therapeutics
Consulting or Advisory Role - ABL Bio; Agenus; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Gilead Sciences; Merck; Pieris Pharmaceuticals; QED Therapeutics; Qurient; Roche; Senti Biosciences; SERVIER; Tallac Therapeutics
Research Funding - Astex Pharmaceuticals; AstraZeneca; Fulgent Genetics
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; Gilead Sciences; GlaxoSmithKline; Incyte; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Silverback Therapeutics; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Debora S. Bruno
Honoraria - AstraZeneca
Consulting or Advisory Role - Amgen; AstraZeneca (I); Bristol Meyers Squibb; Daiichi Sankyo/Astra Zeneca; Lilly; Mirati Therapeutics; Novartis; Syneos Health
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Dragonfly Therapeutics (Inst); Genentech (Inst); Mirati Therapeutics (Inst); Seagen (Inst)
 
David Schröder
Stock and Other Ownership Interests - Abbvie; Gilead Sciences; Johnson & Johnson/Janssen; Merck; Novo Nordisk; Pfizer
 
Mariette Labots
Honoraria - BMS (Inst); Janssen (Inst)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Vitromics (Inst)
 
Stefano Rinaldi
Employment - Dragonfly Therapeutics; Fuhong Therapeutics
 
Amy Holdorf
Employment - Dragonfly Therapeutics
Stock and Other Ownership Interests - Dragonfly Therapeutics (Inst)
 
Violetta Kivovich
Employment - Bristol Myers Squibb; Dragonfly Therapeutics
Stock and Other Ownership Interests - Bristol Myers Squibb
Travel, Accommodations, Expenses - Dragonfly Therapeutics
 
Jean-Marie Cuillerot
Employment - Dragonfly Therapeutics; Dragonfly Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene; Dragonfly Therapeutics
Patents, Royalties, Other Intellectual Property - Patents filed as part of my work for DragonflyTx. I do not own any IP on those (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo/Lilly; MedImmune; Pfizer; Relay Therapeutics
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Foundation Medicine; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape